Asia Executives To Watch: GSK Japan Names Startup Founder VP, Daiichi's New Overseas Division
The spring cherry blossom has ushered in a flurry of new executives to the industry in the Asia Pacific, particularly in Japan where the new fiscal years starts in April for most companies. GSK has taken a bold step to appoint an executive with a previous startup background to its senior leadership in Japan, while Daiichi Sankyo has set up a special division for overseas expansion. Nippon Shinyaku and IQVIA Japan have also made new appointments.
You may also be interested in...
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.